BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
January 10, 2023 07:15 ET
|
BioNTech SE
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and...
Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
November 17, 2022 07:00 ET
|
Immatics N.V.
Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt hohe bestätigte objektive Ansprechrate (confirmed objective response rate, cORR) von 50 % (6/12) bei...
Immatics Announces Third Quarter 2022 Financial Results and Business Update
November 17, 2022 07:00 ET
|
https://immatics.com/
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and...
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 10, 2022 09:00 ET
|
EvolveImmune
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
October 24, 2022 07:00 ET
|
EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
October 20, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
October 18, 2022 07:00 ET
|
EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
October 17, 2022 14:27 ET
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
Immatics gibt garantiertes öffentliches Zeichnungsangebot von Stammaktien im Wert von $110 Millionen bekannt
October 10, 2022 07:37 ET
|
Immatics N.V.
Houston, Texas und Tübingen, Deutschland, 10. Oktober 2022 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
October 10, 2022 07:37 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...